Chemotherapy for recurrent disease and combined modality therapies for head and neck cancer

1995 ◽  
Vol 7 (3) ◽  
pp. 242-247 ◽  
Author(s):  
Ranjana Tavorath ◽  
David G. Pfister
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Recurrent Disease ◽  
Combined Modality ◽  
Combined Modality Therapies

Combined therapy for stage III-IV head and neck cancer: preliminary results.

1984 ◽  
Vol 2 (7) ◽  
pp. 804-810 ◽  
Author(s):  
S H Krasnow ◽  
M H Cohen ◽  
A Johnston-Early ◽  
M L Citron ◽  
B E Fossieck ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Response Rate ◽  
Combined Modality Therapy ◽  
Combined Therapy ◽  
Stage Iii ◽  
Combined Modality Treatment ◽  
Combined Modality ◽  
Rbc Deformability

As part of a combined modality treatment program using chemotherapy, surgery, and/or radiotherapy, 25 patients with previously untreated stage III or IV head and neck cancer received initial combination chemotherapy. Pathologically confirmed complete remission was noted in nine patients (36%). The overall objective major response rate (with all patients included in analysis) was 68%. The chemotherapy regimen included bleomycin, cisplatin, vinblastine, methotrexate, and 5-fluorouracil. A novel concept of drug scheduling was used, based on chemotherapy-induced improvement in RBC deformability. The underlying concept is that improved RBC deformability results in improved capillary blood flow and thereby, increased drug delivery to tumor cells. Treatment resulted in moderate hematologic and renal toxicity with no treatment-related deaths. This exceptionally high, pathologically confirmed complete response rate will hopefully provide a mechanism by which combined modality therapy can adequately be tested for its ability to prolong survival of patients with advanced head and neck cancer.

Squamous Cell Carcinoma Antigen (SCC), Carcinoembryonic Antigen (CEA), and Tumour-Associated Trypsin Inhibitor (TATI) for Monitoring Head and Neck Cancer

1993 ◽  
Vol 8 (2) ◽  
pp. 81-87 ◽  
Author(s):  
D. Pectasides ◽  
J. Bourazanis ◽  
N. Economides ◽  
P. Pozadzidou ◽  
L. Gogou ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Recurrent Disease ◽  
Stage Iv ◽  
Serum Levels ◽  
Tumour Marker ◽  
Individual Therapy ◽  
Early Stages ◽  
Low Sensitivity

Eighty-eight patients with head and neck cancer were prospectively monitored, before and after treatment, by means of simultaneous serum SCC, CEA and TATI measurements. Thirty-two (36.6%) patients had early stages (I, II, III) and 56 (63.4%) advanced (stage IV) or recurrent disease. Pre-treatment serum SCC levels were elevated in 20.4% of patients, CEA in 27.2% and TATI in 4.5%. There was no correlation between the incidence of TATI elevation and tumour burden; this marker did not increase with progressing disease stages. CEA and SCC had low sensitivity in the early stages of head and neck cancer and reached 35.7% (20/56 patients) and 25% (14/56 patients) in stage IV or recurrent disease. Despite the low sensitivity of these tumour markers, there was a correlation between tumour marker levels and the course of the disease. This study indicates that the routine assessment of SCC, CEA and TATI serum levels is of no value. However, it can be used as a potential tool for monitoring the efficacy of individual therapy in both early and advanced stages of head and neck cancer.

Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer

1986 ◽  
Vol 152 (4) ◽  
pp. 451-455 ◽  
Author(s):  
John R. Jacobs ◽  
Julie Kish ◽  
John F. Ensley ◽  
Khurshid Ahmad ◽  
Arthur Weaver ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Combined Modality Therapy ◽  
Combined Modality

Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate-leucovorin chemotherapy

Cancer ◽  
1985 ◽  
Vol 55 (S9) ◽  
pp. 2149-2155 ◽  
Author(s):  
Ralph R. Weichselbaum ◽  
John R. Clark ◽  
Daniel Miller ◽  
Marshall R. Posner ◽  
Thomas J. Ervin
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Combined Modality Treatment ◽  
Combined Modality
Sign in / Sign up

Export Citation Format

Share Document